Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Ratón N-IF: nuevo modelo de fibrosis espontáneo y único

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOSE20180424001
Publicado:
31/05/2018
Caducidad:
01/06/2019
Resumen:
Una pyme creada en una universidad del norte de Suecia especializada en investigación de procesos inflamatorios ofrece un nuevo modelo preclínico, el ratón N-IF, para analizar nuevos medicamentos antifibróticos y antiinflamatorios. Este modelo reduce y simplifica las pruebas y tiene un rendimiento mayor que los modelos actuales. La empresa busca socios con el fin de establecer acuerdos comerciales, así como investigadores que desarrollen medicamentos antifibróticos y antiinflamatorios. Los socios potenciales son compañías farmacéuticas y biotecnológicas o investigadores en CROs.

Details

Tittle:
The N-IF mouse - a novel and unique spontaneous fibrosis model
Summary:
A University origin SME in northern Sweden offers a new pre-clinical model, the N-IF mouse, for testing new anti-fibrotic and anti-inflammatory drugs. The new model shortens and simplifies the tests and are also performing considerable better than the ones existing today. The SME is looking for commercial agreement or research partners that develops anti-fibrotic drugs or anti- inflammatory drugs. The partners can be pharmaceutical companies, biotech companies or high-level researchers at CROs.
Description:
A university origin SME in northern Sweden active in the field of inflammatory research offers a new pre-clinical model, the N-IF mouse, for testing new anti-fibrotic and anti-inflammatory drugs.

The N-IF mouse is an NKT transgenic mouse on the non-obese diabetic (NOD) background. N-IF stands for NOD inflammation and fibrosis.

Fibrosis contributes to approximately 40% of deaths in the industrial world and despite this huge impact on human health no efficient anti-fibrotic drugs are currently available on the market. Numerous pharmaceutical companies are developing anti-fibrotic drugs, but the development is hampered by the lack of good and reliable pre-clinical models for testing of the new drugs.

The scientists and founders of the company have developed a pre-clinical model, which they call the N-IF mouse, for testing of anti-inflammatory and/or anti-fibrotic drugs. The N-IF mouse has several advantages over existing models as the development of fibrosis in the N-IF mouse is spontaneous, proceeded by a chronic inflammation and occurs in several organs.

The company offers their customers e.g. pharmaceutical companies or other interested clients to these the effect of new anti-inflammatory and/or anti-fibrotic drugs on the phenotype of the N-IF mouse.
The company plans, conducts, analyse and report the results of the tests in the model to their clients and the clients provide the substances to be tested. A dialogue about more extended cooperation concerning the pre-clinical model is possible in the future if a client prefers to do the tests in-house.
Advantages and Innovations:
The pre-clinical model developed has several advantages over pre-clinical models available on the market today for testing of new anti-fibrotic drugs:

- Fibrosis seen in the model develops spontaneously and at a young age
- The phenotype is 100% reproducible
- Fibrosis develops in several organs
- Development of fibrosis preceded by a state of chronic inflammation which is what is seen in many human conditions.

Development of fibrosis in the model occurs spontaneously and at a young age. This shortens the test protocols and makes testing faster as well as better accuracy and precision level compared to pre-clinical models available on the market today. The founders predict that this pre-clinical model will become the golden standard for pre-clinical testing of anti-fibrotic drugs.
Stage of Development:
Already on the market
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent application in USA -Y- PCT upcoming

Partner sought

Type and Role of Partner Sought:
Looking for partners such as SME companies, Clinical Research Organisations (CROs) that are subcontractor to "Big Pharma" and "Big Pharma" companies directly. All three that are developing and testing anti-fibrotic and/or anti-inflammatory drugs. We are especially looking for partners who are experienced in the field of liver and/or renal pathology who are interested in testing the effect of their new anti-inflammatory or anti-fibrotic drugs.

The considered models for partnerships are:
1. Commercial agreement with technical assistance- conducts tests in the pre-clinical model using drugs provided by the partner.
2. Research cooperation agreement - to perform research in our focus fields on demand or with partners for further exploitation together.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Swedish

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002005 Ingeniería genética
06001012 Investigaciones médicas
06002008 Microbiología
06001013 Tecnología médica / ingeniería biomédica